Leibovitch Igal, Huilgol Shyamala C, Richards Shawn, Paver Robert, Selva Dinesh
Oculoplastic & Orbital Division, Royal Adelaide Hospital, University of Adelaide, South Australia, Australia.
Dermatol Surg. 2006 Nov;32(11):1364-8. doi: 10.1111/j.1524-4725.2006.32307.x.
There are only a few reports on the outcome with full-thickness skin grafts (FTSG) in defect reconstruction after Mohs micrographic surgery (MMS).
The objective was to evaluate the complications with FTSG in patients treated with MMS for cutaneous tumors.
This study is based on a prospective data collection of all patients in Australia treated with MMS and monitored by the Skin and Cancer Foundation, between 1993 and 2002. Primary outcome measures were FTSG recipient-site complications (partial/complete graft failure, graft infection, acute bleeding/hematoma, graft hypertrophy, and graft contracture).
The study group included 2,673 patients (50.2% men) with a mean age of 64+/-14 years. Most tumors were basal call carcinoma (90.9%) and were located on the nose (63.8%), periocular area (14.8%), or auricular area (8.1%). A total of 11.7% of cases had recipient-site complications (graft hypertrophy, 42.3%; partial graft failure, 27.2%; graft contraction, 15.3%). Only 45.2% of complicated cases required treatment.
Short-term recipient-site complications occurred in less than 12% of reconstructions with FTSG. Graft hypertrophy and partial graft failure accounted for most cases of complications. The authors have indicated no significant interest with commercial supporters.
关于莫氏显微外科手术（MMS）后全厚皮片移植（FTSG）进行缺损修复的结果，仅有少数报道。
评估采用MMS治疗皮肤肿瘤的患者进行FTSG后的并发症。
本研究基于对1993年至2002年间在澳大利亚接受MMS治疗并由皮肤与癌症基金会监测的所有患者的前瞻性数据收集。主要观察指标为FTSG受区并发症（部分/完全移植失败、移植感染、急性出血/血肿、移植肥大和移植挛缩）。
研究组包括2673例患者（男性占50.2%），平均年龄64±14岁。大多数肿瘤为基底细胞癌（90.9%），位于鼻部（63.8%）、眼周区域（14.8%）或耳部区域（8.1%）。共有11.7%的病例出现受区并发症（移植肥大占42.3%；部分移植失败占27.2%；移植挛缩占15.3%）。只有45.2%的复杂病例需要治疗。
FTSG修复术后不到12%的患者出现短期受区并发症。移植肥大和部分移植失败占并发症的大多数。作者声明与商业支持者无重大利益关系。
